1StrutherS AD.Aldosterone escape during ACE inbibitor therapy in chronic heart failure[J].Eur Heart J,1995,16(54PPLN):103-106.
2Thurmann PA,Kenadi P,Schmidt A et al:Influence of the angiotensin I antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension[J].Circulation,1998,98(19):2037-2042.
3Ambrose J.Pribnow DG,Girand GD et a1.Angiotensin type 1 receptor antagomsm with irbesartan inhibits ventricular hypertrophy and improves diastolic function in remodeling postmyocardial in faretion ventricle[J].J Am Soc Nephrol,1999’10(1):129-136.
4Ellis ML,Patterson JH. A new class of antihypertensive therapy:angiotensin Ⅱ receptor antagonists[J].Pharmacotherapy, 1996,16 (5): 849～ 860.
5Meredith PA. Optimal dosing characteristics of the angiotensin Ⅱ receptor antagonist telmisartan [J].Am J Cardiol,1999,84(2A) :7K～12K.
6Marino MR,Langenbacher KM,Ford NE et al. Pharmacodynamics and pharmacokinetics of irbesartan in patients with mild to moderate hypertension [J]. J Cardiovasc Pharmacol Ther, 1999,4 (2): 67 ～ 75.
